KEY POINTS Moderna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers. The mRNA vaccine is currently on the U.S. market under...
Source LinkKEY POINTS Moderna is the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers. The mRNA vaccine is currently on the U.S. market under...
Source Link
Comments